GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Precision BioSciences Inc (NAS:DTIL) » Definitions » Forward PE Ratio

Precision BioSciences (Precision BioSciences) Forward PE Ratio : 0.00 (As of Jun. 09, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Precision BioSciences Forward PE Ratio?

Precision BioSciences's Forward PE Ratio for today is 0.00.

Precision BioSciences's PE Ratio without NRI for today is 0.00.

Precision BioSciences's PE Ratio for today is 0.00.


Precision BioSciences Forward PE Ratio Historical Data

The historical data trend for Precision BioSciences's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Precision BioSciences Forward PE Ratio Chart

Precision BioSciences Annual Data
Trend
Forward PE Ratio

Precision BioSciences Quarterly Data
Forward PE Ratio

Competitive Comparison of Precision BioSciences's Forward PE Ratio

For the Biotechnology subindustry, Precision BioSciences's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Precision BioSciences's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Precision BioSciences's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Precision BioSciences's Forward PE Ratio falls into.



Precision BioSciences Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Precision BioSciences  (NAS:DTIL) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Precision BioSciences Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Precision BioSciences's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Precision BioSciences (Precision BioSciences) Business Description

Traded in Other Exchanges
Address
302 East Pettigrew Street, Dibrell Building, Suite A-100, Durham, NC, USA, 27701
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
Executives
J. Jefferson Smith 10 percent owner C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Alan List officer: Chief Medical Officer C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701
Michael Amoroso director, officer: President and CEO 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Dario Scimeca officer: General Counsel C/O PRECISION BIOSCIENCES, INC., 302 E. PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
John Alexander Kelly officer: Interim CFO C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Pharma Ag Novartis 10 percent owner LICHTSTRASSE 35, CH-4002, BASEL V8
Ag Novartis 10 percent owner LICHTSTRASSE 35, BASEL V8 CH 4056
Derek Jantz director, 10 percent owner, officer: Chief Scientific Officer C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Melinda Brown director 10 HUDSON YARDS, NEW YORK NY 10001
Shari Lisa Pire director C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701
Samuel C. Wadsworth director C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
David S. Thomson officer: Chief Development Officer C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Stanley Frankel director C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701
Matthew R. Kane director, 10 percent owner, officer: President and CEO C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Shane Barton officer: VP & Corporate Controller C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701